Experimental CAR t therapy targets tough childhood leukemia

NCT ID NCT06609928

Recruiting now Disease control Sponsor: Fred Hutchinson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Aug 07, 2026 · Updated 3 times

Summary

This early-phase trial is testing a new type of immune cell therapy called FOLR1 CAR T cells for children aged 6 and under with acute myeloid leukemia (AML) that has come back or not responded to treatment. The therapy involves taking a child's own immune cells, modifying them in the lab to recognize and attack leukemia cells, and infusing them back. The main goals are to see if the treatment is safe and to find the best dose.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: FOLR1 CAR T cells (a type of immune cell therapy)
What this could lead to: If it works, this could point toward a new treatment option for children with hard-to-treat AML that has returned or not responded to standard therapy.
What could go wrong: This is a very early phase 1 trial with only 12 children, so it is primarily testing safety and dosing. The therapy may not work, and there are risks of serious side effects like low blood counts and infections.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia childhood acute myeloid leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RECURRENT CHILDHOOD ACUTE MYELOID LEUKEMIA REFRACTORY CHILDHOOD ACUTE MYELOID LEUKEMIA

Contacts and locations

Locations

Fred Hutch/University of Washington/Seattle Children's Cancer Consortium
RECRUITING

Seattle, Washington, 98109, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.